Hypertension Management: 2026 ACC/AHA Blood Pressure Targets and Treatment Updates

Resistant Hypertension: Diagnosis and Fourth-Line Options

Resistant hypertension (BP above target despite three optimally dosed antihypertensives including a diuretic) affects 10-15% of treated patients. Obstructive sleep apnea should be excluded as a contributing cause. Before diagnosing true resistance, confirm adherence (pill counts, drug levels), exclude white coat effect (ambulatory BP monitoring), and assess for secondary causes including renal artery stenosis. Spironolactone 25-50 mg daily is the recommended fourth-line agent based on the PATHWAY-2 trial, which showed superiority over bisoprolol, doxazosin, and placebo for resistant hypertension[4]. In patients intolerant to spironolactone, bisoprolol 5-10 mg or doxazosin 4-8 mg are alternatives.

Practical Implementation: The Biggest Barriers

The evidence for intensive BP control and combination therapy is strong, but implementation in practice faces predictable barriers. Patients resist taking multiple medications, particularly when hypertension is asymptomatic — the classic challenge of treating a number rather than a symptom. Therapeutic inertia — the failure to intensify treatment when BP is above target — remains the single largest contributor to uncontrolled hypertension, with studies showing clinicians fail to escalate therapy in more than half of visits where BP exceeds target. Single-pill combinations help address both barriers: they reduce pill burden for the patient and create a simpler escalation pathway for the clinician (one prescription to adjust rather than two).

Home blood pressure monitoring is increasingly recognized as superior to office measurements for guiding treatment decisions. Office readings are subject to white coat effect, variable technique, and single-point measurement error. Home monitoring over 5-7 days provides a more reliable estimate of true blood pressure burden and helps patients engage with their own management. When discussing BP targets with patients, framing the conversation around specific risk reduction — "lowering your blood pressure to below 130 reduces your risk of stroke and heart failure by roughly one-quarter" — is more motivating than discussing abstract millimeter numbers.

Limitations and Open Questions

Intensive BP targets are not appropriate for all patients. SPRINT excluded patients with diabetes, prior stroke, and advanced CKD — populations where the optimal target remains less certain. The STEP trial enrolled only Chinese patients, and whether its results fully generalize to other populations is an open question. Orthostatic hypotension risk increases with intensive targets, particularly in elderly patients on multiple antihypertensives, and falls in this population carry serious consequences. The 2026 guidelines appropriately recommend individualization — lower targets for higher-risk patients who tolerate them, with relaxation to below 140 mmHg for those at high fall risk or with limited life expectancy.

References

1. A Randomized Trial of Intensive versus Standard Blood-Pressure Control (SPRINT)
2. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP)
3. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (ACCOMPLISH)
4. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2)
5. Major outcomes in high-risk hypertensive patients to ACE inhibitor, calcium channel blocker, or diuretic (ALLHAT)